The Zacks Analyst Blog features Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies


For Immediate Release

Chicago, IL – March 17, 2023 – announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events affecting stocks and the financial markets. Stocks recently featured on the blog include: Nike, Inc. NKE, Salesforce, Inc. CRM, Zoetis Inc. ZTS, Archer-Daniels-Midland Co. ADM, and Trane Technologies plc TT.

Here are the highlights from Thursday’s analyst blog:

Top research reports for Nike, Salesforce and Zoetis

The Zacks Research Daily presents the best research from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Nike, Inc., Salesforce, Inc. and Zoetis Inc. These research reports were selected from the approximately 70 reports released today by our team of analysts.

You can All current research reports can be found here >>>

shares of Nike are up +10.2% over the past six months versus +10.4% growth in the Zacks footwear and retail apparel industries. The company benefited from brand strength, robust consumer demand and an innovative product pipeline. Its Consumer Direct Acceleration strategy and robust performance across its digital and DTC businesses bode well.

Our model projects revenue growth of 5.5% in fiscal 2023, with growth of 13.2% on a constant currency basis. However, Nike saw gross margin decline due to higher discounts to clear inventory, increased freight and logistics costs, increased input costs and negative currency effects.

The Zacks analyst expects weak gross margin and negative currency effects to continue to weigh on Nike’s results in the coming quarters.

(You You can read the complete research report on NIKE here >>>)

Salesforce Stocks have outperformed the Zacks computer software industry over the past six months (+19.7% vs. +10.6%). The company is benefiting from a robust demand environment as customers undergo an extensive digital transformation. The rapid adoption of its cloud-based solutions is driving demand for its products. His sustained focus on launching better tailored products according to customer needs drives his sales.

Continued deal wins in the international market are another growth driver. The acquisition of Slack would make the company a leader in enterprise team collaboration solutions and better compete with Microsoft’s Teams product. Zacks analyst expects CRM’s revenue to grow at a CAGR of 11.2% through fiscal 2024-2026.

However, tough competition and unfavorable currency fluctuations are a cause for concern. In addition, a difficult macroeconomic environment could weigh on growth prospects in the near term.

(You can Read the full Salesforce research report here >>>)

shares of Zoetis have outperformed the Zacks Medical – Drugs industry (+4.0% versus -5.4%) over the last six months. The company’s momentum continues with its innovative portfolio of pet care parasiticides, including Simparica Trio and dermatology products (Apoquel and Cytopoint). The recently launched chewable version of Apoquel saw strong sales growth.

European acceptance of Librela and Solensia, its new monoclonal antibody (mAb) therapies for osteoarthritis pain in dogs and cats, is encouraging. The introduction of innovative products strengthened the portfolio and should boost growth.

However, the company continues to face supply issues that continue to provide headwinds, along with livestock disease outbreaks that are hurting product demand. Fierce competition from the animal health departments of pharmaceutical companies Merck and Bayer remains a problem.

(You can Read the full research report on Zoetis here >>>)

Other notable reports that we feature today are Archer-Daniels-Midland Co. and Trane Technologies plc.

Why haven’t you checked out Zacks’ top stocks?

Since 2000, our top stock-picking strategies have blown away the S&P’s +6.2 compound annual return. Amazingly, they rose with average gains of +46.4%, +49.5% And +55.2% per year. Today you can access their live picks for free and without obligation.

See shares free >>

media contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. The potential for loss is inherent in every investment. This material is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether an investment is suitable for a is suitable for certain investors. It should not be assumed that investments in any security, company, sector or market identified and described have been or will be profitable. All information is current at the time of publication and is subject to change without notice. Any views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or investment management activities for securities. These returns are from hypothetical portfolios composed of Zacks rank = 1 stocks rebalanced monthly excluding transaction costs. These are not actual stock portfolio returns. The S&P 500 is an unmanaged index. Visit for information on the performance figures presented in this press release.

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click here to get this free report

Salesforce Inc. (CRM): Free Stock Research Report

NIKE, Inc. (NKE): Free Stock Research Report

Archer Daniels Midland Company (ADM): Free Stock Research Report

Zoetis Inc. (ZTS): Free Stock Research Report

Trane Technologies plc (TT): Free stock research report

To read this article on, click here.

Zacks Investment Research

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *